Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
Portfolio Pulse from Benzinga Insights
Sutro Biopharma (NASDAQ:STRO) was analyzed by 10 analysts, showing a mix of bullish and somewhat bullish ratings. The average 12-month price target is now $12.5, down 11.79% from $14.17, with a high estimate of $18.00 and a low of $8.00. Analyst actions include maintaining, lowering, and raising ratings and price targets, reflecting their response to the company's performance and market conditions. Sutro Biopharma, a clinical-stage company focusing on cancer and autoimmune disorders, has shown significant financial growth, with a revenue increase of 1217.44% and a net margin of 27.32%.
May 08, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sutro Biopharma's stock analysis by 10 analysts shows a mix of bullish views, with a revised average price target of $12.5, indicating a cautious but optimistic outlook. The company's significant financial performance, including a revenue growth of 1217.44% and a high net margin, underscores its strong market position and operational efficiency.
The mixed analyst ratings with a slight decrease in the average price target suggest a cautious optimism among analysts, which could lead to a positive short-term impact on STRO's stock price. The company's impressive financial growth and operational efficiency are likely to bolster investor confidence, potentially driving up the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100